The mission of the Neuroendocrine Tumor Research Foundation is to fund research to discover cures and more effective treatments for neuroendocrine cancers.
The Neuroendocrine Tumor Research Foundation is committed to improving the lives of patients, families, and caregivers affected by neuroendocrine cancer by providing information and educational resources.
Driving the search for a cure to neuroendocrine cancer
Since its founding in 2005, NETRF has awarded more than $37 million in research grants to leading scientists at renowned institutions around the world, with the goal of:
- Understanding the molecular basis of the disease to discover vulnerabilities that can be exploited to interrupt the development and progression of NETs.
- Discovering diagnostic and prognostic markers that can guide treatment planning decisions.
- Developing reliable disease models for laboratory experiments of new treatments.
- Creating a collaborative NET scientific community where researchers openly share resources, tools, and ideas.
- Increasing the number of NET researchers focused on discovering breakthroughs in treatment
Improving the lives of those with neuroendocrine cancer
The Neuroendocrine Tumor Research Foundation is committed to improving, extending, and saving the lives of those affected by neuroendocrine cancer by providing information and educational resources.
- Online resources to help newly diagnosed patients chart their course and practical information to help NET survivors live their best life.
- Searchable databases of NET specialists and patient support groups in the U.S.
- Regional patient and caregiver conferences bring together patients and providers to discuss the latest tests and treatments.
- Multimedia library of the latest information on treatment and disease management approaches.
Read our most recent annual report.
Recruiting young researchers to study NETs
Bringing researchers together to share knowledge and resources
Funding the world’s top researchers
Million in NET research funding
$
0
M
of every dollar spent in 2023 supported research and education.
0
¢
Of patients have advanced disease when diagnosed with NETs
0
%